Evidence from Acute Psychological Studies CBD reduced THC-induced anxiety when administered. CBD as an anxiolytic drug · Antidepressant-Like and Anxiolytic-Like Effects of Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of. People interested in managing their anxiety with CBD oil should look exclusively at research on cannabidiol, not generalized studies of medical.
study cbd oil anxiety
Cannabidiol also binds to these receptors but does not produce a high. Proponents argue that cannabidiol oil has many health benefits, ranging from slowing the growth of cancer to improved mental health. CBD oil is edible and can be used as a cooking oil or added to food. People may also take it as a medication by consuming a few drops. CBD oil should not be smoked, and there is no evidence that smoking it offers any benefits.
CBD oil derived from hemp will not produce a "high. Unlike other cannabis plants, hemp has not been specially bred to produce high levels of THC. Cannabidiol may be sold as a type of hemp oil with trace amounts of THC. So, someone using cannabidiol might still test positive for THC on a drug test, even though they will not experience any alterations of mental state after using the oil.
Much of the research on cannabis products has looked at the use of marijuana rather than at CBD oil as a standalone product. Some studies have found that cannabis might help anxiety. Others suggest that having anxiety is a risk factor for recreational marijuana use, or that using marijuana can make a person more vulnerable to anxiety. People interested in managing their anxiety with CBD oil should look exclusively at research on cannabidiol, not generalized studies of medical marijuana.
Although there are fewer studies on cannabidiol specifically, the preliminary research is promising. A small study found that cannabidiol could reduce symptoms of social anxiety in people with social anxiety disorder SAD. Brain scans of participants revealed changes in blood flow to the regions of the brain linked to feelings of anxiety.
In this study, cannabidiol not only made participants feel better but also changed the way their brains responded to anxiety. A study also found that cannabidiol could reduce social anxiety.
For that study, researchers looked specifically at cannabidiol to treat anxiety associated with public speaking. Research published in found that CBD oil had anti-anxiety and antidepressant effects in an animal model.
A analysis of previous studies concluded that CBD oil is a promising treatment for numerous forms of anxiety, including social anxiety disorder, panic disorder, obsessive-compulsive disorder , generalized anxiety disorder, and post-traumatic stress disorder. The report cautioned, however, that data on long-term use of CBD oil is limited. While research strongly points to the role of cannabidiol in treating short-term anxiety, little is known about its long-term effects, or how it can be used as a prolonged treatment.
A case study explored whether cannabidiol could reduce symptoms of post-traumatic stress disorder PTSD and anxiety-provoked sleep disorder in a child with a history of trauma. Researchers found that cannabidiol reduced the child's anxiety and helped her sleep. Research on the use of cannabis suggests that it may have negative health effects, particularly when smoked.
Research specifically on cannabidiol, however, has found few or no negative side effects. This means CBD oil may be a good option for people who do not tolerate the side effects of other medications for anxiety, including addiction. Not all states in the United States have specifically legalized CBD oil, although some have legalized it for only specific purposes.
A person should educate themselves about the potential risks of purchasing or using it. Because CBD oil is not regulated as a medical treatment for anxiety, it is unclear what dosage a person should use, or how frequently they should use it. A person should consult a doctor who has experience with CBD oil to determine the right dosage for their needs.
The role of cannabidiol as a treatment for anxiety disorders remains unclear, as more long-term studies are required to assess the benefits and risks. For people with anxiety who have gotten no relief from other treatments, however, CBD oil offers a potential alternative solution. People considering CBD oil for anxiety should speak with a doctor to help determine the right treatment for them. People are also advised to research the laws in their area regarding the use of cannabis products.
CBD oil is available for purchase online. Is it risky to take CBD oil for anxiety while it has not been approved for this use? The use of marijuana is becoming more common, but that does not guarantee it is safe, or free of contaminants or other drugs. There has been acute poisoning reported from synthetic cannabinoids. The substantial burden of anxiety-related disorders and the limitations of current treatments place a high priority on developing novel pharmaceutical treatments.
CBD has broad therapeutic properties across a range of neuropsychiatric disorders, stemming from diverse central nervous system actions [ 11 , 12 ]. In recent years, CBD has attracted increasing interest as a potential anxiolytic treatment [ 13 — 15 ].
The purpose of this review is to assess evidence from current preclinical, clinical, and epidemiological studies pertaining to the potential risks and benefits of CBD as a treatment for anxiety disorders. In total, 49 primary preclinical, clinical, or epidemiological studies were included.
Neuroimaging studies that documented results from anxiety-related tasks, or resting neural activity, were included. THC ratio , were included. Cannabis sativa , a species of the Cannabis genus of flowering plants, is one of the most frequently used illicit recreational substances in Western culture.
The 2 major phyto- cannabinoid constituents with central nervous system activity are THC, responsible for the euphoric and mind-altering effects, and CBD, which lacks these psychoactive effects. Preclinical and clinical studies show CBD possesses a wide range of therapeutic properties, including antipsychotic, analgesic, neuroprotective, anticonvulsant, antiemetic, antioxidant, anti-inflammatory, antiarthritic, and antineoplastic properties see [ 11 , 12 , 16 — 19 ] for reviews.
Pharmacology relevant to these actions is detailed below. The primary mechanism by which eCBs regulate synaptic function is retrograde signaling, wherein eCBs produced by depolarization of the postsynaptic neuron activate presynaptic CB 1 Rs, leading to inhibition of neurotransmitter release [ 23 ].
Interactions with the TRPV1 receptor, in particular, appear to be critical in regulating the extent to which eCB release leads to inhibition or facilitation of presynaptic neurotransmitter release [ 25 ]. TRPV1 receptors are also expressed in the brain, including the amygdala, periaqueductal grey, hippocampus, and other areas [ 26 , 27 ].
The eCB system regulates diverse physiological functions, including caloric energy balance and immune function [ 28 ]. The eCB system is also integral to regulation of emotional behavior, being essential to forms of synaptic plasticity that determine learning and response to emotionally salient, particularly highly aversive events [ 29 , 30 ]. Activation of CB 1 Rs produces anxiolytic effects in various models of unconditioned fear, relevant to multiple anxiety disorder symptom domains reviewed in [ 30 — 33 ].
Regarding conditioned fear, the effect of CB 1 R activation is complex: CB 1 R activation may enhance or reduce fear expression, depending on brain locus and the eCB ligand [ 34 ]; however, CB 1 R activation potently enhances fear extinction [ 35 ], and can prevent fear reconsolidation. Genetic manipulations that impede CB 1 R activation are anxiogenic [ 35 ], and individuals with eCB system gene polymorphisms that reduce eCB tone—for example, FAAH gene polymorphisms—exhibit physiological, psychological, and neuroimaging features consistent with impaired fear regulation [ 36 ].
Reduction of AEA—CB 1 R signaling in the amygdala mediates the anxiogenic effects of corticotropin-releasing hormone [ 37 ], and CB 1 R activation is essential to negative feedback of the neuroendocrine stress response, and protects against the adverse effects of chronic stress [ 38 , 39 ]. Accordingly, CB 1 R activation has been suggested as a target for anxiolytic drug development [ 15 , 43 , 44 ]. In addition to dose-dependent activation of TRPV1 channels, the anxiogenic versus anxiolytic balance of CB 1 R agonists also depends on dynamic factors, including environmental stressors [ 33 , 49 ].
In preclinical studies, 5-HT 1A R agonists are anxiolytic in animal models of general anxiety [ 51 ], prevent the adverse effects of stress [ 52 ], and enhance fear extinction [ 53 ]. They are expressed on serotonergic neurons in the raphe, where they exert autoinhibitory function, and various other brain areas involved in fear and anxiety [ 54 , 55 ].
Mechanisms underlying the anxiolytic effects of 5-HT 1A R activation are complex, varying between both brain region, and pre- versus postsynaptic locus, and are not fully established [ 56 ]. Initial studies of CBD in these models showed conflicting results: When tested over a wide range of doses in further studies, the anxiolytic effects of CBD presented a bell-shaped dose—response curve, with anxiolytic effects observed at moderate but not higher doses [ 61 , 90 ].
All further studies of acute systemic CBD without prior stress showed anxiolytic effects or no effect [ 62 , 65 ], the latter study involving intracerebroventricular rather than the intraperitoneal route.
No anxiogenic effects of acute systemic CBD dosing in models of general anxiety have yet been reported. As yet, few studies have examined chronic dosing effects of CBD in models of generalized anxiety. Anxiolytic effects in models used: Anxiolytic effects of CBD in models of generalized anxiety have been linked to specific receptor mechanisms and brain regions.
The midbrain dorsal periaqueductal gray DPAG is integral to anxiety, orchestrating autonomic and behavioral responses to threat [ 91 ], and DPAG stimulation in humans produces feelings of intense distress and dread [ 92 ]. The bed nucleus of the stria terminalis BNST serves as a principal output structure of the amygdaloid complex to coordinate sustained fear responses, relevant to anxiety [ 93 ]. In the prelimbic cortex, which drives expression of fear responses via connections with the amygdala [ 94 ], CBD had more complex effects: As noted, CBD has been found to have a bell-shaped response curve, with higher doses being ineffective.
Stress is an important contributor to anxiety disorders, and traumatic stress exposure is essential to the development of PTSD.
In a chronic study, systemic CBD prevented increased anxiety produced by chronic unpredictable stress, in addition to increasing hippocampal AEA; these anxiolytic effects depended upon CB 1 R activation and hippocampal neurogenesis, as demonstrated by genetic ablation techniques [ 81 ]. Finally, CBD, partially via CB 1 Rs, decreased defensive immobility and explosive escape caused by bicuculline-induced neuronal activation in the superior colliculus [ 89 ].
Several studies assessed CBD using contextual fear conditioning. Briefly, this paradigm involves pairing a neutral context, the conditioned stimulus CS , with an aversive unconditioned stimulus US , a mild foot shock. After repeated pairings, the subject learns that the CS predicts the US, and subsequent CS presentation elicits freezing and other physiological responses. By contrast, CBD microinjection in the infralimbic cortex enhanced conditioned freezing [ 70 ].
Finally, El Batsh et al. In this study, CBD was administered prior to conditioning rather than prior to re-exposure as in acute studies, thus further directly comparable studies are required. CBD has also been shown to enhance extinction of contextually conditioned fear responses.
Extinction training involves repeated CS exposure in the absence of the US, leading to the formation of a new memory that inhibits fear responses and a decline in freezing over subsequent training sessions. Further studies showed CB 1 Rs in the infralimbic cortex may be involved in this effect [ 82 ].
CBD also blocked reconsolidation of aversive memories in rat [ 76 ]. Briefly, fear memories, when reactivated by re-exposure retrieval , enter into a labile state in which the memory trace may either be reconsolidated or extinguished [ 97 ], and this process may be pharmacologically modulated to achieve reconsolidation blockade or extinction. Overall, existing preclinical evidence strongly supports the potential of CBD as a treatment for anxiety disorders.
Activation of 5-HT 1A Rs appears to mediate anxiolytic and panicolytic effects, in addition to reducing conditioned fear expression, although CB 1 R activation may play a limited role. While CBD predominantly has acute anxiolytic effects, some species discrepancies are apparent. In addition, effects may be contingent on prior stress and vary according to brain region.
Further receptor-specific studies may elucidate the receptor specific basis of this distinct dose response profile. Further studies are also required to establish the efficacy of CBD when administered in chronic dosing, as relatively few relevant studies exist, with mixed results, including both anxiolytic and anxiogenic outcomes. In particular, results show potential for the treatment of multiple PTSD symptom domains, including reducing arousal and avoidance, preventing the long-term adverse effects of stress, as well as enhancing the extinction and blocking the reconsolidation of persistent fear memories.
The anxiolytic effects of CBD in humans were first demonstrated in the context of reversing the anxiogenic effects of THC. CBD reduced THC-induced anxiety when administered simultaneously with this agent, but had no effect on baseline anxiety when administered alone [ 99 , ]. Further studies using higher doses supported a lack of anxiolytic effects at baseline [ , ].
By contrast, CBD potently reduces experimentally induced anxiety or fear. CBD reduced anxiety associated with a simulated public speaking test in healthy subjects, and in subjects with SAD, showing a comparable efficacy to ipsapirone a 5-HT 1A R agonist or diazepam [ 98 , ].
CBD also reduced the presumed anticipatory anxiety associated with undergoing a single-photon emission computed tomography SPECT imaging procedure, in both healthy and SAD subjects [ , ]. Finally, CBD enhanced extinction of fear memories in healthy volunteers: These rCBF changes were not correlated with anxiolytic effects [ ].
In a series of placebo-controlled studies involving 15 healthy volunteers, Fusar-Poli et al. Response activation is diminished in PTSD and other anxiety disorders, and increased activation predicts response to treatment [ ]. CBD produced no changes in predicted areas relative to placebo but reduced activation in the left insula, superior temporal gyrus, and transverse temporal gyrus.
The fearful faces task activates the amygdala, and other medial temporal areas involved in emotion processing, and heightened amygdala response activation has been reported in anxiety disorders, including GAD and PTSD [ , ]. CBD attenuated blood-oxygen-level dependent activation in the left amygdala, and the anterior and posterior cingulate cortex in response to intensely fearful faces, and also reduced amplitude in skin conductance fluctuation, which was highly correlated with amygdala activation [ ].
Dynamic causal modeling analysis in this data set further showed CBD reduced forward functional connectivity between the amygdala and anterior cingulate cortex [ ]. Epidemiological studies of various neuropsychiatric disorders indicate that a higher CBD content in chronically consumed cannabis may protect against adverse effects of THC, including psychotic symptoms, drug cravings, memory loss, and hippocampal gray matter loss [ — ] reviewed in [ ].
As THC acutely induces anxiety, this pattern may also be evident for chronic anxiety symptoms. Two studies were identified, including an uncontrolled retrospective study in civilian patients with PTSD patients [ ], and a case study in a patient with severe sexual abuse-related PTSD [ ], which showed that chronic cannabis use significantly reduces PTSD symptoms; however, these studies did not include data on the THC: Thus, overall, no outcome data are currently available regarding the chronic effects of CBD in the treatment of anxiety symptoms, nor do any data exist regarding the potential protective effects of CBD on anxiety potentially induced by chronic THC use.
Evidence from human studies strongly supports the potential for CBD as a treatment for anxiety disorders: Limited results in healthy subjects also support the efficacy of CBD in acutely enhancing fear extinction, suggesting potential for the treatment of PTSD, or for enhancing cognitive behavioral therapy. Further studies are also required to establish whether chronic, in addition to acute CBD dosing is anxiolytic in human.
Human experimental findings support preclinical findings, and also suggest a lack of anxiogenic effects, minimal sedative effects, and an excellent safety profile. Overall, this review emphasizes the potential value and need for further study of CBD in the treatment of anxiety disorders.
Disclosure forms provided by the authors are available with the online version of this article. Studies repeatedly recognize the prevalence of an anxiety-provoked sleep disorder after a traumatic experience. A review of the literature suggests some benefits from the use of CBD because of its anxiolytic and sleep-inducing effects.
The strength of this particular case is that our patient was receiving no pharmaceutical medications other than nonprescription diphenhydramine but only nutritional supplements and the CBD oil to control her symptoms. Her scores on the sleep scale and the anxiety scale consistently and steadily decreased during a period of 5 months see Table 2. She was ultimately able to sleep through the night most nights in her own room, was less anxious at school and home, and displayed appropriate behaviors.
Her anxiety is not gone, but it is not as intense and she is much easier to be around. She now sleeps in her own room most of the time, which has never happened before. We do not have a reasonable foundation to recommend dosing from the scientific literature. However, in our experience, this supplement given 12 mg to 25 mg once daily appears to provide relief of key symptoms with minimal side effects.
Our patient did not voice any complaints or discomfort from the use of CBD. We routinely asked about headache, fatigue, and change in appetite or agitation in addition to conducting a routine psychiatric evaluation. Although CBD is considered generally safe, 17 the long-term effects are yet to be studied. The ultimate goal is to gradually taper her off the use of CBD oil and transition our patient into lifelong coping strategies such as yoga, meditation, and various other therapeutic activities.
Scientific data indicate the potential therapeutic value of cannabinoid drugs, primarily [tetrahydrocannabinol], for pain relief, control of nausea and vomiting, and appetite stimulation; smoked marijuana, however, is a crude [tetrahydrocannabinol] delivery system that also delivers harmful substances.
No financial support was provided. Further research articles listed. National Center for Biotechnology Information , U. Journal List Perm J v. Published online Oct Copyright and License information Disclaimer. This article has been cited by other articles in PMC. Abstract Introduction Anxiety and sleep disorders are often the result of posttraumatic stress disorder and can contribute to an impaired ability to focus and to demonstration of oppositional behaviors.
Case Presentation These symptoms were present in our patient, a ten-year-old girl who was sexually abused and had minimal parental supervision as a young child under the age of five.
Discussion Cannabidiol oil, an increasingly popular treatment of anxiety and sleep issues, has been documented as being an effective alternative to pharmaceutical medications. History of sexual abuse and neglect. PTSD secondary to sexual abuse. February 16, , laboratory values: Started counseling; Cooperative and good behavior at counseling session.
Behavior still very rough; sleep poor. Started imipramine therapy, 25 mg at bedtime March 7, ECG was normal August 8, a Good summer. Overall better sleep and energy with imipramine therapy. Imipramine, 25 mg at bedtime January 21, Returned for evaluation and treatment after 3 years. Suicidal ideation; cut self on leg; defiant and stubborn. Had psychotherapy 3 years straight twice a month. Has outbursts at school. Mood is more at ease. Open in a separate window.
Anxiety Relief Without The High? New Studies On CBD, A Cannabis Extract
For people with anxiety, CBD oil is touted as an all-natural way to find relief. Find out whether this marijuana compound can help ease your. This proposed study aims to evaluate the efficacy of daily Cannabidiol (CBD) Oil Capsules in treating symptoms of DSM-5 anxiety disorders. It may help treat conditions like pain, insomnia, and anxiety. In numerous studies, CBD was able to reduce the number of seizures, and .. CBD oil was recommended by my son who has arthritis and, for me, it really works.